mL/min and 72.6 mL/min (pϭ0.059) but similar at-6month, 80.2 mL/min and 72.2 mL/min (pϭ0.167). Conclusions: High dose atorvastatin treatment does not prevent CIN in patients receiving primary angioplasty. However it demonstrated potential of lowering CIN in patients with renal insufficiency and elderly.
Background: Blood transfusion is associated with acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) . We sought to elucidate in more detail the relation between blood transfusion and AKI and its effects on short-and long-term mortality. Methods: 995 patients with aortic stenosis underwent TAVI with the Medtronic-CoreValve or the Edwards Valve in 7 centers. AKI was defined by the Valve Academic Research Consortium (absolute increase in serum creatinine Ն0.3 mg/dl (Ն26.4 mol/l) or Ն50% increase Յ72 hr). Logistic and Cox regression was used for predictor and survival analysis. Results: AKI occurred in 20.7% (nϭ206). The number of units of blood transfusion Յ24 hr was the strongest predictor of AKI (Ն 5 units, Potential triggers of blood transfusion such as baseline anemia, bleeding-vascular complications and peri-operative blood loss were not identified as predictors. Patients with severe baseline anemia had 2.4 times less blood loss but on average received 2.3 fold more units of blood transfusions in comparison to patients without anemia before TAVI (pϽ0.001). AKI and life-threatening bleeding were independent predictors of 30-day mortality (OR: 3.04 [1.52-6.07], OR: 5.39 [2.14-13.57], respectively) while transfusion (Ն3 units), baseline anemia and AKI predicted mortality beyond 30 days. Conclusions: AKI occurred in 21% of the patients after TAVI. The number of blood transfusions but not the indication of transfusion predicted AKI. AKI was a predictor of both short-and long-term mortality whereas blood transfusion predicted long-term mortality. These findings indicate that outcome of TAVI may be improved by more restrictive use of blood transfusions.
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Impact of Chronic Kidney Disease on Myocardial Infarct Size and Adverse Events in ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI Trial
Usman Baber 1 , Roxana Mehran 2 , Sorin Brener 3 , Akiko Maehara 4 , Dariusz Dudek 5 , Thomas Neunteufl 6 , D. Christopher Metzger 7 , C. Michael Gibson 8 , Gregg Stone 9 1 Mount Sinai School of Medicine, New York, NY, 2 Mount SInai School of Medicine, New York, NY, 3 New York Methodist Hospital, Brooklyn, NY, 4 Cardiovascular Reserach Foundation and Columbia University Medical Center, New York, NY, 5 University Hospital, Krakow, Poland, 6 AKH Vienna Austria, Vienna, Vienna, 7 Wellmont CVA Heart Institute, Kingsport, USA, Boston, USA, 9 Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY Background: Chronic kidney disease (CKD) patients have less favorable outcomes after ST-elevation myocardial infarction (STEMI) for yet unclear reasons. Methods: The INFUSE-AMI trial randomized patients with STEMI due to proximal or mid LAD occlusion to intracoronary bolus abciximab (ClearWay RX catheter) vs. no abciximab, and to thrombus aspiration (Export) vs. no aspiration. We compared infarct size as % of LV mass assessed by magnetic resonance imaging at 30-days, myocardial reperfusion and incidence of adverse events between patients with vs. patietns without CKD. CKD was defined as a creatinine clearance Ͻ 60 ml/min. Results: Patients with CKD (nϭ59, 14.4%) were older, more often female, diabetic and less likely to undergo angiography within 3 hours of symptom onset (50.8% vs. 72.2%, pϭ0.001) compared to those without CKD (nϭ349, 85.5%). Following PCI, final thrombolysis in myocardial infarction (TIMI) 3 flow (86.4 vs. 92.8%, pϭ0.12) and myocardial blush grade (MBG) 3 (64.4% vs. 70.5%, pϭ0.35) was observed similarly in both groups. Median infarct size was non-significantly larger in CKD patients (19.3% vs. 17.0%, pϭ0.34). The incidence of 30-day adverse events, were significantly higher in those with CKD (Figure) . There were no significant differences in stent thrombosis, reinfarction or revascularization between groups.
Conclusions:
Differences in infarct size between patients with and without CKD presenting with STEMI are modest and unlikely to account for the significantly higher short-term cardiac risk in those with CKD.
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Prognostic Value of Different Definitions of Contrast Induced Acute Kidney Injury in STEMI: Analysis from the HORIZONS-AMI Trial
Rudolf Jarai 1 , George Dangas 2 , Kurt Huber 3 , Roxana Mehran 4 , Gregg Stone 5 , Ke Xu 6 1 Wilhleminenhospital, Vienna, Austria, 2 Department of Cardiology, Mount Sinai Medical Center, New York, New York City, NY, 3 Dept Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria, Vienna, Austria, 4 Mount Sinai Hosptial, New York, USA, 5 Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, 6 Cardiovascular Research Foundation, New York, NY Background: Several definitions of acute kidney injury (AKI) are in use, and the optimal absolute and relative increase of serum creatinine increase after contrast administration to define contrast-media induced acute kidney injury (CI-AKI) is still a matter of debate. Moreover, the prognostic relevance of AKI according to the varying definitions in STEMI has not been established. Methods: Serum creatinine concentration data within 48h after coronary angiography was present in 2975 STEMI pts in the HORIZONS-AMI trial. Patients were analyzed according to different AKI definitions (AKIN-, modified AKIN-(mAKIN), Waikar-Bonventre (W-B), percent-changes of creatinine (Ͻ25%, 26-50%; 51-75%; Ͼ75%) and to the commonly used "standard-definition" of a relative increase in serum creatinine of Ն25% or an absolute increase of Ն0.5 mg/dL). The primary endpoint was all-cause mortality at 3 years. Results: Depending on definitions the incidence of CI-AKI ranged from 5.0% to 15.5%. Similarly, 3-year mortality rates differed substantially with respect to the different CI-AKI definitions (Table) . Absolute changes of creatinine were strongly associated with all-cause mortality, starting with an increase of 0.3mg/dl absolute increase of creatinine above baseline (HR 3.68 pϽ0.001; Figure) -the cutoff level used in the AKIN-and modified AKIN-definitions. The increased risk associated with Ͼ0.3mg/dl absolute increase of creatinine was independent of the amount of contrast-media used. 
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